Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring (“ODM”), has told DirectorsTalk that it has added two additional accounts to its platform programme in the USA.
The first account, the sixth platform account in the Company’s West Coast territory, is a major hospital in the San Francisco Bay Area. The hospital has placed an initial order for 50 probes and is contracted to buy a minimum of 30 probes per month going forward.
The second account comprises a collection of hospitals in the Company’s North-East territory who are working collaboratively to introduce enhanced recovery protocols in bowel surgery with a view to spreading into other types of surgery in due course. The Company is active in two of the participating hospitals, one of which is a large teaching hospital.
These are Deltex’s sixth and seventh new platform programme accounts in 2016, bringing the total number of US platform accounts to 24. This further illustrates the success of the Company’s ongoing strategy to focus on the USA and develop it as its key market.
Ewan Phillips, Deltex Medical’s Chief Executive, commented: “Adoption rates in the USA, our key territory for development, continue to outperform our other areas of focus. Additional platform accounts contribute to recurring sales growth in the USA, where probe revenues in the five months to the end of May are over 50% ahead of the corresponding period in 2015.
“We look forward to adding further accounts to our platform account network and meeting our key milestone of 30 platform accounts in the US in the coming months.”
